Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer by Berruti, A & Kerkhofs, T
  
1 
 
 
 
 
 
This is the author's final version of the contribution published as: 
 
Berruti A
1
, Fassnacht M
2
, Haak H
3
, Else T
4
, Baudin E
5
, Sperone P
6
, Kroiss M
7
, Kerkhofs T
3
, Williams 
AR
4
, Ardito A
8
, Leboulleux S
5
, Volante M
9
, Deutschbein T
7
, Feelders R
10
, Ronchi C
7
, Grisanti S
11
, 
Gelderblom H
12
, Porpiglia F
13
, Papotti M
9
, Hammer GD
4
, Allolio B
7
, Terzolo M
8
. 
 
 
Prognostic role of overt hypercortisolism in completely operated 
patients with adrenocortical cancer. 
 
 
Eur Urol.; 65(4); 2014; 832-8. DOI: 10.1016/j.eururo.2013.11.006. 
 
 
The publisher's version is available at: 
 
http://www.sciencedirect.com/science/article/pii/S0302283813012037 
 
 
 
 
 
 
 
 
This full text was downloaded from iris-Aperto: https://iris.unito.it/  
 
 
 
 
 
 
  
2 
PROGNOSTIC ROLE OF OVERT HYPERCORTISOLISM  IN COMPLETELY OPERATED 
PATIENTS WITH ADRENOCORTICAL CANCER  
1Alfredo Berruti, 2,7Martin Fassnacht, 3Harm Haak, 4Tobias Else, 5Eric Baudin, 6Paola Sperone,  
7Matthias Kroiss, 3Thomas Kerhofs, 4Andrew R Williams, 8Arianna Ardito, 5Sophie Leboulleux,  
9Marco Volante, 7Timo Deutschbein, 10Richards Feelders, 7Cristina Ronchi, 1Salvatore Grisanti,  
11Hans Gelderblom, 12Francesco Porpiglia, 9Mauro Papotti, 4Gary D Hammer, 7Bruno Allolio, 
8Massimo Terzolo. 
1Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, 
University of Brescia, Spedali Civili Hospital, Brescia,Italy 
2
 Department of Internal Medicine IV, University Clinic, Munich, Germany  
3Internal Medicine, Maxima Medical Centre, Eindhoven, The Netherlands; 
4Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of 
Michigan Health System, Ann Arbor, MI, USA 
5Endocrine Oncology and Nuclear Medicine, Goustave Roussy Institute, Villejuif, France; 
6Department of Oncology, University of Turin, Medical Oncology Unit, San Luigi Gonzaga 
Hospital, Orbassano, Italy 
 7 Department of Medicine I, Endocrine Unit, University Hospital of Würzburg, Germany  
8Department of Clinical and Biological Sciences, University of Turin, Internal Medicine I, S. 
Luigi Gonzaga Hospital, Orbassano, Italy 
9Department of Oncology, University of Turin, Pathology Unit, S. Luigi Gonzaga Hospital, 
Orbassano, Italy 
10Erasmus MC Rotterdam, The Netherlands 
11Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands 
12Department of Oncology, University of Turin, Urology Unit, S. Luigi Gonzaga Hospital, 
Orbassano, Italy 
Word count: 2711 
Text: 2411 
Abstract: 300 
  
3 
Running title: cortisol secretion and prognosis 
 
Key words: adrenocortical cancer, adjuvant therapy, Cushing syndrome, mitotane. 
 
Ackowledgement: This study is a collaborative effort of the ACC working group of the 
European Network for the Study of Adrenal Tumors (ENS@T) and the Michigan University 
(USA). The study was supported in part by by Regione Piemonte Ricerca Sanitaria Finalizzata 
2008 prot No 20889/DA20.01 and the European Network for the Study of Adrenal Tumors 
(ENS@T) (FP7/2007-2013 under grant agreement n° 259735). In addition, this study was 
supported by grants of the Deutsche Krebshilfe (# 106 080 to BA and MF and # 107 111 to 
MF). 
Correspondence:  
Alfredo Berruti MD 
Oncologia Medica 
Azienda Ospedaliera Spedali Civili 
Piazzale Spedali Civili 1 
20123 Brescia, Italy 
TEL +39 030 3995410 
Fax +39 030 3700017 
Email: alfredo.berruti@gmail.com 
 
  
4 
ABSTRACT   
Background: although prognostic parameters are important to guide adjuvant treatment, very 
few have been identified in patients with completely resected adrenocortical carcinoma (ACC). 
Objective: to assess the prognostic role of clinical symptoms of hypercortisolism in a large 
series of completely operated ACC. 
Setting and participants: a total of 524 patients followed at referral centers for ACC in Europe 
and the USA entered the study. Inclusion criteria: age 18 years or older, histological diagnosis 
of ACC, radical surgery (R0). Exclusion criteria: history of other malignancies and adjuvant 
systemic therapies other than mitotane. 
Intervention: all ACC patients were completely resected, adjuvant mitotane therapy was 
prescribed at the discretion of the investigators. 
Outcome measurement and statistical analysis: the primary endpoint was overall survival 
(OS), the secondary endpoints were the recurrence-free survival (RFS) and the efficacy of 
adjuvant mitotane therapy according to cortisol secretion.  
Results and limitations: overt hypercortisolism was observed in 202 patients (38.6%). 
Patients with cortisol excess were younger (p=0.002), while no difference according to sex 
and tumor stage was observed.  
The median follow-up of the series was 50 months. After adjustment for sex, age, tumor 
stage and mitotane treatment, the prognostic significance of cortisol excess was highly 
significant  for both  RFS (HR 1.30, 95% CI: 1.04-2.62, p=0.02) and OS (HR 1.55, 95% CI: 
1.15-2.09, p=0.004). Mitotane administration was associated with a reduction of disease 
progression (adjusted HR 0.65, 95% CI: 0.49-0.86; p=0.003), that did not differ according to 
the patient secretory status. 
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A major limitation is that only symptomatic patients were considered as having 
hypercortisolism, thus excluding information on the prognostic role of elevated hormone 
levels in the absence of a clinical syndrome. 
Conclusion: clinically relevant hypercortisolism  is a new prognostic factor in radically 
operated ACC that can be considered in the decision making process to prescribe or not 
adjuvant therapy.
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INTRODUCTION 
Adrenocortical carcinoma (ACC) is a rare tumor characterized by a dismal prognosis with less 
than 50% of patients surviving more than 5 years after diagnosis (1). Complete surgical 
resection of ACC offers the best chance for prolonged survival, particularly in patients 
diagnosed at an early stage and with low proliferating tumors (1); however, a significant 
number of patients without objective and biochemical evidence of residual disease after 
surgery are destined to relapse (2-4). 
The aggressive behavior and the high recurrence rate of the majority of ACC patients provide 
the rationale for the use of adjuvant therapy. For decades mitotane has been the only 
approved drug for ACC therapy (5). In a case control study involving 177 patients, the 
outcome in 47 patients treated in Italian reference centers systematically using adjuvant 
mitotane therapy after radical surgery was significantly improved (in terms of both recurrence  
free survival and overall survival) in comparison to 55 Italian patients and 75 German patients 
treated at institutions not administering adjuvant mitotane therapy [6]. 
Although these data cannot be considered conclusive, mitotane is recommended  (7) and 
increasingly prescribed in ACC patients who underwent a complete resection and are at high 
risk of recurrence. However, only very few prognostic factors are currently available to 
identify patients at risk. Few molecules have been proposed as prognostic and predictive 
markers (8-12) but none of them are used in clinical practice. Currently only disease stage, 
completeness of initial resection and proliferation index are the widely accepted prognostic 
factors (13-14). However, they are not sufficiently accurate to predict the outcome of every 
individual and risk stratification remains challenging, at least for a subset of patients. 
Consequently new prognostic factors are needed. 
Two previous reports suggested cortisol secretion as a negative prognostic factor in ACC 
patients. In a large single Institution French series including 202 patients with different 
disease stages, cortisol excess was found to be an independent prognostic factor for overall 
survival and was predictive of subsequent metastatic disease in the subset of patients with 
stage I to III disease at diagnosis (15).  Similar results were obtained from a series of 72 
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Italian patients submitted to chemotherapy with EDP (Etoposide, Doxorubicin and Cisplatin) 
plus mitotane (16). Noteworthy, in the French series a significant interaction was found 
between cortisol over-production and mitotane therapy and in a subsequent letter on the 
same series the authors reported a trend towards improved outcomes for patients with 
cortisol-overproducing tumors subjected to adjuvant mitotane therapy (17). Conversely, 
cortisol excess failed to be associated with prognosis in another single Institution French 
series involving metastatic ACC patients (18).    
In the  current study, the prognostic role of cortisol excess  at diagnosis was investigated in a 
large multicenter, multinational series of patients who underwent complete resection. A 
secondary aim of the study was to explore the efficacy of adjuvant mitotane therapy dividing 
patients according to the cortisol excess status. 
 
METHODS 
This retrospective analysis was carried out in 5 cohorts of patients with ACC collected from 
several centers in Italy, Germany and the Netherlands and from two single Institutions in 
France (Goustave Roussy Institute) and USA (University of Michigan), respectively. All 
patients had undergone radical surgery.  
The patients were recruited between 1990 and 2008. Median follow-up was 50 months.  
The primary aim was to demonstrate the prognostic role in terms of survival of clinical 
symptoms and sign of hypercortisolism in ACC patients who underwent complete resection. 
Secondary aims were the prognostic role of overt hypercortisolism on the progression free 
survival (PFS) and the efficacy of adjuvant mitotane therapy dividing patients according to 
the cortisol excess status.    
To be included in the study the patients had to meet the following inclusion criteria: age 18 
years or older, histological diagnosis of ACC, radical surgery (R0) and a postoperative ECOG 
performance status of 0 to 1. Exclusion criteria were incomplete resection, history of other 
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malignancies within the previous five years, and adjuvant systemic therapies other than 
mitotane (i.e. cytotoxic chemotherapy). Adjuvant radiation therapy of the tumor bed was 
allowed.  
All data were obtained by reviewing patient medical records. Data were retrieved by 
trained medical personnel using specifically tailored data forms. We collected data on patient 
clinical and demographical characteristics, date of diagnosis, tumor stage at diagnosis, 
physical exam, clinical symptoms and signs of hormone hypersecretion,  date and type of 
surgery, pathology report,  date of recurrence, and either date of death or date of the last 
follow-up visit. In all cases, the presence of clinical signs and syndromes prompted a 
hormone work-up.  
The institutional ethics committee at each clinical center approved the study. 
Complete resection was defined as no evidence of macroscopic residual disease on the 
basis of surgical reports and histopathological analysis. The great majority of diagnoses were 
confirmed by reference pathologists. Staging at diagnosis was based on imaging studies and 
was corroborated by the findings at surgery. Staging was reported according to the ENS@T 
staging system  (19). Disease recurrence was defined as unequivocal radiologic evidence of a 
new tumor lesion during follow-up. Definition of the functional status of ACC was based on 
clinical symptoms and signs of hormone excess. Patients with elevated hormone levels 
without a clinical syndrome were not considered hypersecreting. 
Statistical Analysis 
All statistical analyses were performed by using the “Statistica” software (Statsoft Inc., 
Tulsa, OK, USA). Rates and proportions were calculated for categorical data, and medians 
and ranges for continuous data. Differences in continuous variables were analyzed by means 
of the two-tailed Mann-Whitney U test. For categorical variables, differences were analyzed 
by means of the chi square test. Recurrence-free survival (RFS) was measured from the date 
of surgery to the date of recurrence; for patients who did not have a relapse, the data were 
censored at the date of the last follow-up visit. Overall survival (OS) was measured from the 
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date of surgery to the date of death, and the data were censored at the date of the last 
follow-up visit. Survival curves were computed using the Kaplan-Meier method and were 
compared using the log-rank test. The independent prognostic role of the secretory status 
was also assessed in multivariate analysis according to the Cox model. Recurrence-free 
survival and overall survival were the dependent variables, the covariates included were 
cortisol excess, age, sex and mitotane  treatment. Due to the limited number of patients with 
mitotic count  available and the risk of biased data, mitotic and proliferation indexes  were 
not added in the multivariate model. The Cox analysis was also employed to assess the 
presence of heterogeneity in the prognostic effect of the hormone excess  status in patients 
stratified according to various prognostic factors and the prognostic role of mitotane 
treatment according to the secretory status. A modification of prognostic effect in these 
subgroups was assessed by including the appropriate covariate interaction term(s) in the 
model. This procedure is equivalent to a test of the homogeneity of the hazard ratios 
associated with functional status or mitotane treatment in the strata. Missing data led to 
patient exclusion from particular analyses. All p-values reported are the result of two-sided 
tests. p-values of less than 0.05 were considered to indicate statistical significance.  
RESULTS 
Five hundred twenty-four patients entered the study. The patient characteristics are shown 
in Table 1. No patients had metastases. Recurrence was documented in 339 patients 
(64.7%). Death occurred in 204 patients (38.9%). Clinical signs of cortisol plus/minus  other 
hormone excess was observed in 202 patients (38.6%), clinical hyperandrogenism in 58 
patients (11.1 %). Seven patients (1.3 %) had symptoms and signs of pure mineralocorticoid 
excess, 9 patients (1.8%) had clinical evidences of estrogen excess, while the remaining 247 
(47.2%) patients had clinically non-functional tumors. 
The distribution of cortisol excess according to demography showed no difference 
according to sex (125/321, 38.9% in women; 72/203, 35.5% in men; p=0.42), whereas an 
inverse relationship was found with age (divided according to tertile distribution) (p=0.002). 
The distribution of cortisol secretion did not differ stratifying patients according to stage 
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(126/336, 37.5% in patients with stage I and II; 71/188, 37.8% in patients with stage III; 
Table 2). No relationship was also found between cortisol excess and mitotic index (in the 
patient subset in whom both parameters were available) and patients with or without 
adjuvant mitotane (Table 2). 
Prognostic role of cortisol secretory status 
In univariate analysis, cortisol excess was associated with a decreased RFS (just failing to 
attain the statistical significance, p=0.088) (figure 1a) and a significant decrease in overall 
survival (p=0.044) (figure 1b). The prognostic significance of the secretory status was highly 
significant after adjustment for sex, age, tumor stage and adjuvant mitotane treatment in the 
multivariate analysis for both RFS (HR 1.30, 95% CI: 1.04-1.62, p=0.02) and OS (HR 1.55, 
95% CI: 1,15-2,09, p=0.004) (Table 3). 
Variation in the prognostic role of cortisol excess status according to participating country, 
sex, age and tumor stage 
We performed a further explorative analysis aiming to assess the heterogeneity of the 
prognostic role of the cortisol excess status according to country, sex, age and tumor stage 
and the data are displayed in Table 4. 
 Despite some variability, there was no significant difference among  the HR for recurrence 
and death of cortisol excess across the subgroups from the different countries (p for 
interaction 0.58 and 0.20, respectively). 
Stratifying patients according to demographic and clinical parameters, the HR for clinical 
cortisol excess versus no cortisol excess in terms of RFS did not significantly differ dividing 
patients according to age, sex and tumor stage (Table 4). In terms of OS, however, a greater 
HR for death was observed in more advanced stage (III) versus early stage (I-II) of disease 
(interaction test, p=0.018) (Table 4).  
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 Prognostic role of mitotane therapy according to the cortisol excess status 
Adjuvant mitotane (Lysodren®, Bristol-Meyers, Squibb, New York, USA and HRA Pharma, 
Paris, France) was prescribed to 251 patients (47.9%): 105 patients in the Italian series 
(55.0%), 34 patients in the French series (91.4%), 30 patients in the Netherland series 
(46.2%), 28 patients in the Michigan series (36.4%) and 54 patients in the German series 
(35.1%).  
In the overall series, mitotane administration was associated with a significant reduction of 
disease relapse in multivariate analysis adjusting for sex, age and stage  (HR 0.65, 95% CI: 
0.49-0.86; p=0.003). Of note the prognostic impact on RFS of mitotane therapy did not differ 
according to the cortisol-excess  status [no cortisol excess  HR 0.68, 95% CI: 0.51-0.90, 
cortisol excess  HR 0.65, 95% CI: 0.46-0.93; interaction test p=0.79] (figure 2a). Conversely 
mitotane treatment failed to be significantly associated with a lower risk of death (adjusted 
HR 0.82, 95% CI: 0.60-1.10; p=0.18), without any difference stratifying patients according to 
the clinical hypercortisolism status [cortisol excess  HR 0.85, 95% CI: 0.57-1.28, no  cortisol 
excess HR 0.71, 95% CI 0.44-1.13; interaction test p=0.67] (figure 2b).  
Discussion 
One of the major determinants of the variability in the clinical presentation of ACC is the 
presence and type of hormone secretion (14).  Hormone-secreting tumors most frequently 
produce cortisol. In this multinational study we demonstrated for the first time in a large 
series of radically operated ACC patients that the presence of clinical signs of cortisol excess  
is prognostically relevant either in terms of RFS or in terms of overall survival applying  a 
multivariate analysis after adjustment  for commonly recognized prognostic factors. This is an 
important observation since very few prognostic parameters are known in this subset (7-10). 
The mechanism underlying this relationship however is not clear. While in patients with 
metastatic disease hypercortisolism is a killer per se due to immunosuppression, katabolism 
and infection (15,16), these issues cannot be taken into account in patients who underwent 
radical resection and in whom the Cushing’s syndrome has attained a complete remission.  
Our data are consistent with the hypothesis that cortisol-excess  is associated  with a more 
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aggressive disease, although no correlation was found between cortisol excess and mitotic 
index in the subset of patients in whom such information was available. These data suggest 
that other mechanisms than tumor proliferation activity  have to be taken into account to 
support the association between hypercortisolism  and tumor aggressiveness. For instance, it 
was recently suggested that SKG1 protein expression was inversely associated with cortisol 
hypersecretion and that low SGK1 represents a negative prognostic factor in ACC (20). In 
addition, the chronic exposure to elevated cortisol levels before surgery, leading to 
immunosuppression, may favour the development of micrometastases.  
A limitation of this study is represented by the fact that only symptomatic patients were 
considered as having hypercortisolism, thus excluding information on the prognostic role of 
elevated hormone levels in the absence of a clinical syndrome. It should be noted, however, 
that our data can be generalized in ACC patients undergoing surgery outside of reference 
centers in which a complete  hormone work-up is not routinely performed in the absence of 
symptoms. A prospective study testing the prognostic role of cortisol levels in either 
symtomatic or asymptomatic patients should be of interest.  
 Proliferative activity  was found to be a strong prognostic factor in radically operated ACC (7-
9). Due to the limited proportion of patients having mitosis assessed in the present study, this 
parameter was not added to the independent variables included in the multivariate analysis   
and this is a further limitation. The absence of correlation between cortisol secretion and 
mitosis, however,  makes the dependency between the 2 parameters in the multivariate 
prognostic model not probable. 
The HR for progression and death showed a high variation among  participating centers 
reflecting patient selection, but these HRs did not significantly differ at the interaction test. 
In our series adjuvant mitotane after surgery was generally prescribed in patients at higher 
risk of relapse but the criteria adopted were not uniform across centers. This is the reason 
why the proportion of patients who received the drug varied a lot according to countries. The 
French series was recruited in a big oncology center where patients with poorest prognostic 
features are usually addressed as compared with surgery or endocrinological centers. This 
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explain why the great majority of French patients were addressed to mitotane. These 
limitations notwithstanding, in this multinational study patients receiving adjuvant mitotane 
showed a better prognosis in terms of DFS and a non significant  survival improvement than 
patient who did not, confirming the results of a previously published case control study (6).    
In a French series of 166 radically operated patients,  the efficacy of mitotane administration 
on  DFS improvement was not demonstrated in the overall population, although a in the 
subgroup of patients with hypercortisolism  a beneficial tendency was evident (17). 
In the present study the efficacy of mitotane administration on DFS did not differ  when 
patients were stratifyed according to the presence of cortisol excess or not status. These data 
further support the antineoplastic activity of mitotane irrespective of the cortisol excess  
status.    
In conclusion, the present study demonstrates that hypercortisolism  is a new prognostic 
factor in radically operated ACC that can be considered in the decision making process to 
prescribe or not adjuvant therapy. The mechanisms underlying  the relationship between 
cortisol secretion and prognosis in this patient subset deserve elucidation.    
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Legends to figures: 
Figure 1: prognostic role of clinical cortisol hypersecretion in terms of relapse free survival  
(1a) and overall survival (1b) in patients with adrenocortical carcinoma who underwent 
radical resection  
Figure 2: Forrest plot of prognostic impact of adjuvant mitotane therapy versus no therapy in 
terms of relapse free survival (2a) and overall survival (2b) in patients with adrenocortical 
carcinoma who underwent radical resection. Data are adjusted Hazard Ratio for sex, age and 
disease stage. Either overall patients or patient stratified according to cortisol hypersecretory 
status were considered.   
 
 
